MYSOLINE
Pronunciation: PRI-mi-doen


What it isDeoxybarbiturate antiepileptic that is active on its own; only 15–25% is oxidized to phenobarbital, most of a dose leaves unchanged, and the largest metabolite, PEMA, is inert in tremor.
Why this oneWith propranolol it is one of only two first-line treatments for essential tremor, and the tremor effect is primidone’s own: one dose quiets tremor for up to a day while phenobarbital and PEMA are still barely measurable. Not a controlled substance.
What limits itA severe acute reaction on the first dose is common, so start at a fraction of the target. It is an enzyme inducer through its phenobarbital metabolite.
Animated chart of estimated U.S. prescriptions per year, Antiseizure meds (1869–2026). Primidone enters in 1954 (estimated).
Principal riskSedation; converts to phenobarbital
Legacy pregnancy categoryD
Defining liabilitySedation, dependence and phenobarbital-mediated respiratory/CNS depression in overdose.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Epilepsy (grand mal, psychomotor, focal), no prior treatment | Adult & child ≥8 yr | 100-125 mg QHS | 250 mg TID | 500 mg QID (2000 mg/day) |
| Epilepsy | Pediatric <8 yr | 50 mg QHS | 125-250 mg TID (or 10-25 mg/kg/day divided) | 250 mg TID |
Titration Increase approximately every 3 days per initiation schedule (Days 1-3, 4-6, 7-9, then maintenance)
Renal Undefined
Hepatic Undefined
Target serum primidone level 5-12 mcg/mL
Available strengths
Pregnancy Undefined
Lactation Undefined
Generic entry2001
Open Primidone in the interactive console ↗
Open Primidone in the interactive console ↗